InvestorsHub Logo
Followers 4
Posts 129
Boards Moderated 0
Alias Born 05/11/2016

Re: gotinearly post# 41420

Wednesday, 04/14/2021 7:15:33 AM

Wednesday, April 14, 2021 7:15:33 AM

Post# of 118361
Immuno-Oncology patents around NR2F6 are the key assets IMO. That they discovered (a) small molecules that activate and (b) small molecules that inhibit the NR2F6 checkpoint is a very, very big deal. I believe Regen (via Harry Landers) is the first to solve that puzzle for the NR2F6 checkpoint.

For background on other system checkpoints and Immuno-Oncology ...

https://www.cancerresearch.org/immunotherapy/treatment-types/immunomodulators-checkpoint-inhibitors

WT